Lower cardiorenal risk with <scp>sodium‐glucose</scp> cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study

Kåre I. Birkeland, Johan Bodegard, Amitava Banerjee, Dae Jung Kim, Anna Norhammar, Jan W. Eriksson, Marcus Thuresson, Suguru Okami, Kyoung Hwa Ha, Nils Kossack, Jil Billy Mamza, Ruiqi Zhang, Toshitaka Yajima, Issei Komuro, Takashi Kadowaki

Open source

DOI: 10.1111/dom.14189
Published: 2020-09-28
Container: Diabetes, Obesity and Metabolism
Publisher: Wiley
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1111/dom.14189,
  title = {Lower cardiorenal risk with
                    <scp>sodium‐glucose</scp>
                    cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study},
  author = {Kåre I. Birkeland and Johan Bodegard and Amitava Banerjee and Dae Jung Kim and Anna Norhammar and Jan W. Eriksson and Marcus Thuresson and Suguru Okami and Kyoung Hwa Ha and Nils Kossack and Jil Billy Mamza and Ruiqi Zhang and Toshitaka Yajima and Issei Komuro and Takashi Kadowaki},
  year = {2020},
  journal = {Diabetes, Obesity and Metabolism},
  doi = {10.1111/dom.14189},
  url = {https://doi.org/10.1111/dom.14189}
}

RIS

TY  - JOUR
TI  - Lower cardiorenal risk with
                    <scp>sodium‐glucose</scp>
                    cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study
AU  - Kåre I. Birkeland
AU  - Johan Bodegard
AU  - Amitava Banerjee
AU  - Dae Jung Kim
AU  - Anna Norhammar
AU  - Jan W. Eriksson
AU  - Marcus Thuresson
AU  - Suguru Okami
AU  - Kyoung Hwa Ha
AU  - Nils Kossack
AU  - Jil Billy Mamza
AU  - Ruiqi Zhang
AU  - Toshitaka Yajima
AU  - Issei Komuro
AU  - Takashi Kadowaki
PY  - 2020
JO  - Diabetes, Obesity and Metabolism
DO  - 10.1111/dom.14189
UR  - https://doi.org/10.1111/dom.14189
ER  -

APA

Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., Thuresson, M., Okami, S., Ha, K. H., Kossack, N., Mamza, J. B., Zhang, R., Yajima, T., Komuro, I., & Kadowaki, T. (2020). Lower cardiorenal risk with <scp>sodium‐glucose</scp> cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14189

Source records

crossref · retrieved 2026-09-26T22:28:55.440Z